Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd
SHH: 603707.SS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Tang Yongqun
- Employees
- 1,451
- Headquarters
- Nanjing, China
- IPO year
- 2017
- Market cap
- CN¥14.7B
- Website
- https://www.nkf-pharma.com
Loading 603707…
Loading profile data…Frequently asked questions about 603707
What does Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) do?
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd manufactures and sells heparin sodium and low molecular weight heparin products for pharmaceutical companies in the People's Republic of China. It offers enoxaparin sodium, dalteparin sodium, and naqu heparin calcium injections. The company also exports its products primarily to the Europea...
Where does 603707.SS trade?
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) trades on the Shanghai Stock Exchange.
What sector is 603707.SS in?
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd?
Tang Yongqun is the chief executive officer of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS).
Where is Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd headquartered?
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd is headquartered in China.
Does 603707.SS pay a dividend?
Yes — Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) paid a trailing twelve-month dividend of CNY 0.10 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 603707.SS go public?
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS) completed its initial public offering in 2017.